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Objectives This study evaluated the impact of hyperhomocysteinemia (HHcy) on the CD40/CD40 ligand (CD40L) dyad in
vivo and in vitro.
Background Hyperhomocysteinemia is associated with an increased incidence of atherothrombosis, although the molecular
mechanisms of this association are incompletely defined. The CD40L pair triggers inflammatory signals in cells
of the vascular wall, representing a major pathogenetic pathway of atherosclerosis.
Methods We used a commercially available enzyme-linked immunosorbent assay kit to evaluate circulating levels of solu-
ble (s) CD40L in 24 patients with HHcy and 24 healthy subjects. We also used real-time polymerase chain reac-
tion and flow cytometry to determine expression levels of CD40 and vascular cell adhesion molecule (VCAM)-1 in
human umbilical vein endothelial cells (HUVECs) and of CD40L in human platelets.
Results The sCD40L levels were significantly increased in HHcy patients (median [interquartile range] 8.0 [0.7 to 10.5]
ng/ml vs. 2.1 [1.9 to 2.3] ng/ml, p  0.0001). Positive correlations were noted between log sCD40L and log
homocysteine (Hcy) (R  0.68, p  0.0001) or log sVCAM-1 (R  0.41, p  0.005). Homocysteine significantly
stimulated CD40 mRNA expression in HUVECs (p  0.033). Consistently, 24-h exposure to Hcy increased the
percentage of CD40-expressing cells (p  0.00025). Homocysteine also significantly enhanced CD40L expres-
sion in platelets (p  0.025) to a comparable extent as that of thrombin. Notably, Hcy increased VCAM-1 protein
expression induced by CD40L in HUVECs (p  0.0046).
Conclusions The present results uncover a potential molecular target of Hcy, namely the CD40/CD40L dyad. Collectively, they
indicate that upregulation of CD40/CD40L signaling may represent a link between HHcy and an increased risk
of cardiovascular disease. (J Am Coll Cardiol 2007;49:2182–90) © 2007 by the American College of Cardiol-
ogy Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.02.044C
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llevated homocysteine (Hcy) concentration, determined by
enetic or dietary factors, is recognized as an independent
isk factor for cardiovascular disease (1). Homocysteine may
romote vascular damage and atherothrombosis by a num-
er of mechanisms, including release of proinflammatory
ediators, induction of oxidative and endoplasmic reticu-
um stress, and activation of apoptotic pathways in vascular
ells (2). However, the relative contribution of these pro-
esses to the causal relationship between hyperhomocys-
einemia (HHcy) and atherothrombosis is still under
ebate.
rom the *Department of Medicine, Gabriele d’Annunzio University Foundation,
hieti-Pescara, Italy; †Laboratory of Vascular Biology and Pharmacology, Consorzio
ario Negri Sud, San Maria Imbaro, Italy; ‡Department of Biomedical Sciences and
ging Research Center, Gabriele d’Annunzio University Foundation, Chieti, Italy;
nd §Civil Hospital, Pescara, Italy. Supported in part by a grant from the Italian
inistry of Research to the Center of Excellence on Aging of the University of Chieti
to Drs. Davì and Romano).c
Manuscript received January 31, 2006; revised manuscript received December 20,
006; accepted February 9, 2007.Accumulating evidence supports the involvement of
D40/CD40 ligand (CD40L) signaling in atherosclerosis.
oth CD40 and CD40L are expressed by vascular cells,
acrophages, and platelets (3,4). The CD40/CD40L en-
agement on the surface of endothelial cells, smooth muscle
ells, or macrophages triggers a potent inflammatory re-
ponse, characterized by the release of inflammatory cyto-
ines (interleukins 1, 6, 8, 12) and chemokines (monocyte
hemoattractant protein-1), expression of adhesion mole-
ules (E-selectin, vascular cell adhesion molecule [VCAM]-
, intercellular adhesion molecule-1, P-selectin), activation
f matrix metalloproteinases, and procoagulant tissue factor
3–7). Antibody blockade or genetic disruption of CD40L
n Apolipoprotein-E/ mice provides direct evidence of
he involvement of CD40/CD40L signaling in atheroscle-
osis progression (8,9).
A soluble form of CD40L (sCD40L) is rapidly released
y T cells and activated platelets (10,11). The sCD40L
evels are increased in a number of pathological conditions
haracterized by cardiovascular damage, i.e., unstable angina
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June 5, 2007:2182–90 Homocysteine and the CD40/CD40L Dyad11), acute coronary syndromes (12), hypercholesterolemia
13,14), arterial hypertension (15), and diabetes (16). Thus,
easurement of sCD40L is now regarded as an index of
latelet activation and inflammatory vascular damage.
Because HHcy is associated with signs of vascular inflam-
ation and platelet activation (17,18), we tested the hy-
othesis that Hcy may up-regulate the CD40/CD40L
ystem. Here we provide the first evidence of increased
CD40L circulating levels in HHcy patients and of CD40
p-regulation by Hcy in human umbilical vein endothelial
ells (HUVECs) and of CD40L in platelets.
ethods
eagents. Rabbit anti-CD40 and anti-CD40L polyclonal
mmunoglobulin (Ig) G were from Santa Cruz Biotechnol-
gy (Santa Cruz, California). Mouse anti-VCAM-1
CD106) phycoerythrin-conjugated was from BioLegend
San Diego, California). Anti-rabbit fluorescein-conjugate
gG was from Calbiochem (Milan, Italy). The spin/vacuum
otal RNA isolation system was from Promega (Milan,
taly). Reagents for real-time analysis were from Applied
iosystems (Milan, Italy). Human thrombin (2,000 NIH
/mg protein); N-2 hydroxyethyl piperazine-N 1-2-
thanesulfonic acid (HEPES); ethylene glycol-bis (b-
minoethyl ether)-N, N, N=, N=,-tetraacetic acid (EGTA);
rostaglandin E1 (PGE1); DL-homocysteine; L-cysteine;
nd all other chemicals were purchased from Sigma-Aldrich
Milan, Italy). Thrombin was dissolved in saline at 20
mol/l (50 U/ml) and stored at 20°C until use.
atients, genotyping, and measurements. We selected 24
ubjects carrying the 5,10 methylene tetrahydrofolate reduc-
ase (MTHFR) C677T genotype with HHcy (15 mol/l)
nd 24 age- and gender-matched subjects, also expressing
he MTHFR C677T polymorphism, but with normal
omocysteinemia (15 mol/l). Exclusion criteria were
epresented by a recent history of thrombotic events (6
onths), pregnancy or delivery in the previous 6 months,
ypercholesterolemia, diabetes, current medication for birth
ontrol or hormone replacement therapy, and recent use of
spirin, ticlopidine, clopidogrel, anti-inflammatory drugs,
itamin supplements, or anticoagulant agents. Among the
8 patients, 21 (44%) had clinical evidence of vascular
isease, in particular, angina pectoris (n  4), myocardial
nfarction (n  3), transient ischemic attack (n  2), stroke
n 1), and peripheral artery disease (n 2). Nine patients
ad suffered deep venous thrombosis or pulmonary embo-
ism. Patient characteristics are summarized in Table 1.
Subjects were studied as outpatients after a 12-h fast.
lood samples were obtained in the morning. Informed
onsent was obtained from each subject after approval of the
rotocol by the local institutional ethics committee.
Analysis of the MTHFR C677T mutation was carried
ut by digestion with the restriction enzyme Hinf I. The
ection of the gene containing the mutation was amplified
y polymerase chain reaction as described previously (19). tFasting plasma total Hcy (the
um of free and protein-bound
orms plus cysteine-homocysteine
ixed disulfide) was measured in
1 ethylenediaminetetraacetic acid
EDTA)-anticoagulated blood
amples immediately refrigerated
o prevent in vitro total Hcy for-
ation. Plasma was stored at
80°C. The total Hcy was mea-
ured using the Imx Hcy assay
Abbott Park, Illinois). Plasma
CD40L and sVCAM-1 levels
ere measured using specific im-
unoassays (R & D Systems) ac-
ording to the instructions of the
anufacturer. Intra-assay and
nter-assay coefficients of variation
ere 6%.
ells. Human umbilical vein
ndothelial cells were isolated
rom umbilical cords obtained
rom randomly selected healthy
others delivering at the Chieti
niversity Hospital, using 0.1%
ollagenase at 37°C. Cells were
rown on 1.5% gelatin-coated
lates in medium Dulbecco’s
odified Eagle’s medium (D-MEM)/M-199 (50:50) sup-
lemented with 20% heat-inactivated fetal calf serum, 10
g/ml heparin, 50 g/ml endothelial cell growth factor
ECGF), 50 mg/ml penicillin/streptomycin in 5% CO2 at
7°C, and used within 4 passages. Before treatment,
UVECs were made quiescent with D-MEM/M-199
50:50) medium supplemented with 1% bovine serum albu-
in (BSA) and 50 g/ml ECGF for 20 h. Homocysteine
as delivered to cells in D-MEM/F12 (50:50) with 2% fetal
alf serum and ECGF.
For platelet isolation, blood was collected from healthy
olunteers who had not received any medication for at least
weeks. Platelet-rich plasma was prepared by centrifuga-
ion at 200g for 15 min. Platelets were isolated by centrif-
gation at 1,100g for 15 min, after addition to platelet-rich
lasma of 1 mol/l PGE1. The pellet was suspended in
EPES-tyrode containing 1 mol/l PGE1 and 5 mmol/l
GTA and centrifuged at 1,100g for 10 min. Platelets were
uspended with HEPES-tyrode buffer containing 1 mmol/l
a2 at the concentration of 1  108/ml.
eal-time polymerase chain reaction. Total cellular RNA
as extracted using the SV total RNA Isolation System
Promega). Polyadenosine RNA was reverse-transcribed for
0 min at 42°C with StrataScript II (50 U/ml) (Stratagene,
ilan, Italy). Real-time measurements of CD40 were
arried out using the Assay-on-Demand Hs00374176 from
pplied Biosystems, in the ABI PRISM 7900 HT appara-
Abbreviations
and Acronyms
BSA  bovine serum
albumin
CD40L  CD40 ligand
EDTA  ethylenediaminetetra-
acetic acid
Hcy  homocysteine
HEPES  N-2 hydroxyethyl
piperazine-N 1-2-
ethanesulfonic acid
HHcy 
hyperhomocysteinemia
HUVECs  human umbilical
vein endothelial cells
Ig  immunoglobulin
MFI  mean fluorescence
intensity
MTHFR  5,10 methylene
tetrahydrofolate reductase
NF  nuclear factor
PBS  phosphate-buffered
saline
s  soluble
VCAM  vascular cell
adhesion moleculeus, according to the instructions of the manufacturer.
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Homocysteine and the CD40/CD40L Dyad June 5, 2007:2182–90lyceraldehyde-3-phosphate dehydrogenase was used as
he housekeeping gene. Data were elaborated with the SDS
.0 software (Applied Biosystems, Foster City, California).
elative gene expression was evaluated using the 2Ct
ormula.
low cytometric analysis. The HUVECs were harvested
ith phosphate-buffered saline (PBS)/EDTA, washed with
BS/0.5% BSA, and incubated with a polyclonal antibody
gainst human CD40 (1:25 dilution, 1 g for 5  105 cells)
or 30 min at 4°C. Cells were then exposed to a secondary
uorescein-conjugate anti-rabbit antibody for 30 min at
°C. Samples were washed with PBS/0.5% BSA and ana-
yzed in a Becton Dickinson FACScan flow cytometer
Becton Dickinson, Milan, Italy). Data were analyzed using
he CellQuest software. Washed platelets (1  108/ml)
ere exposed to stimuli for 5 min at 37°C, and then
ncubated with anti-CD40L polyclonal IgG (1 g for 5 
06 cells) or control rabbit polyclonal IgG for 30 min at 4°C.
amples were then exposed to a fluorescein-conjugate goat
nti-rabbit IgG antibody (4°C, 30 min), fixed with 2%
araformaldehyde for 1 h at room temperature and analyzed
y FACScan. The CD40L specific mean fluorescence
ntensity (MFI) was calculated by subtracting the value of
he isotype-matched control antibody from that of the
pecific antibody. For evaluation of VCAM-1 expression,
UVECs were grown in EGM-2MV medium (Cambrex
io Science, Walkersville, Maryland) supplemented with
rowth factors. At subconfluence, cells were washed twice
ith PBS and incubated with vehicle or Hcy for 24 h. Cells
ere then exposed to sCD40L (Bender MedSystem, Bur-
ingame, California) for 6 h. The HUVECs were harvested
Clinical Characteristics of MTHFR 677 C¡T CaHomocysteine >15 mol/l Compared With Tho
Table 1 Clinical Characteristics of MTHFR 6Homocysteine >15 mol/l Compar
Variable
Homoc
>15 mol/
Gender, M/F 12/
Age, yrs (mean  SD) 40
Homocysteine, mol/l (mean  SD) 23.6
Subjects with
1 additional cardiovascular risk factor 5
2 additional cardiovascular risk factors 2
3 additional cardiovascular risk factors 1
Vascular disease (%)
Arterial 6
Venous 4
Smoking 4
Hypertension 3
BMI 28 kg/m2 2
Total cholesterol, mg/dl (mean  SD) 176
HDL, mg/dl (mean  SD) 49
LDL, mg/dl (mean  SD) 102
Triglycerides, mg/dl (mean  SD) 116
Renal disease 0
Diabetes 1
BMI  body mass index; HDL  high-density lipoprotein; LDL  low-dnd washed as above, suspended in buffer containing PBS tSA (0.5%), and incubated with anti-human VCAM-1
CD106) conjugated with phycoerythrin (20 l/106 cells) or
sotype-matched IgG1-phycoerythrin (Sigma Aldrich, Mi-
an, Italy) in the dark for 30 min at 4°C. Cells were analyzed
n a Becton Dickinson FacsCalibur flow cytometer. A total
f 10,000 events were acquired. The VCAM-1–specific
FI was calculated using the CellQest analysis software by
ubtracting the value of the isotype-matched antibody from
hat of the specific antibody.
estern blot analysis. Proteins were separated by 10%
odium dodecyl sulfate polyacrylamide gel electrophoresis
SDS/PAGE) under reducing conditions and blotted onto
itrocellulose membranes. These were exposed, in 10%
efatted dry milk, tris-buffered saline 1, 0.1% tween-20,
o a rabbit polyclonal anti-CD40 IgG (1:200 dilution for
h), followed by a secondary anti-rabbit IgG peroxidase-
onjugate antibody (1:5,000 dilution for 1 h). Immunoblots
ere visualized by the enhanced chemoluminescence system,
nd CD40 protein levels were normalized with -actin.
tatistical analysis. Differences between individuals with
lasma Hcy 15 mol/l and individuals with Hcy 15
mol/l were evaluated using the 2-sample t test, Mann-
hitney U test, and chi-square test, as appropriate. In view
f the skewed distribution of homocysteine (skewness 
.9; after log transformation skewness  0.6), sVCAM-1
skewness  1.3; after log transformation skewness  0.7)
nd sCD40L (skewness  1.2; after log transformation
kewness  0.6), these variables were log-transformed for
orrelation analysis and for subsequent multiple-linear re-
ression analysis. For correlation analysis, the Pearson
orrelation coefficient was calculated (nonparametrically dis-
With Plasmaith Homocysteine <15 mol/l
¡T Carriers With Plasma
ith Those With Homocysteine <15 mol/l
e Homocysteine p Value
(Student t Test)24) <15 mol/l (n  24)
12/12 NS
41 13 NS
8.9 2.3 0.0001
4 NS
2 NS
0 NS
6
5
2
2
1
169 24 NS
48 7 NS
100 15 NS
124 41 NS
0
1
ipoprotein; MTHFR  5,10 methylene tetrahydrofolate reductase.rriersse W
77 C
ed W
ystein
l (n 
12
12
13.8
22
8
14
38ributed variables examined after log transformation). Data
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June 5, 2007:2182–90 Homocysteine and the CD40/CD40L Dyadre presented as mean (SD) or as median and interquartile
ange (25th, 75th percentile). Only values of p  0.05 were
egarded as statistically significant. All tests were 2-tailed,
nd analyses were performed using a computer software
ackage (Statistica 6, StatSoft Inc., Tulsa, Oklahoma, or
tatistical Package for the Social Sciences, version 13, SPSS
nc., Chicago, Illinois).
In vitro results are reported as mean  SD. Statistical
nalyses were performed using the Student t test. Values of
 0.05 were considered statistically significant.
esults
Hcy is associated with increased levels of sCD40L and
VCAM-1. To determine whether the CD40/CD40L sys-
Figure 1 Impact of Homocysteinemia
on sCD40L and sVCAM-1 Levels
The sCD40L (A) and sVCAM-1 (B) levels in patients carrying the MTHFR C677T
genotype with hyperhomocysteinemia (15 mol/l) or normal homocysteine-
mia (15 mol/l). Dots represent individual measurements. Horizontal lines
represent median value. Differences between the 2 groups were determined
using the Mann-Whitney U test. MTHFR  5,10 methylene tetrahydrofolate
reductase; sCD40L  soluble CD40 ligand; sVCAM  soluble vascular cell
adhesion molecule.em is regulated by Hcy levels, we measured sCD40L in 2roups of subjects carrying the MTHFR C677T mutation,
ut with different plasma Hcy levels. As shown in Table 1,
he incidence of cardiovascular risk factors was comparable
n the 2 groups, thus excluding potentially confounding
actors. Individuals with plasma Hcy 15 mol/l had
igher sCD40L concentrations compared with subjects
ith Hcy 15 mol/l (median [interquartile range]: 8.0
6.7 to 10.5] vs. 2.1 [1.9 to 2.3] ng/ml, p  0.0001) (Fig.
A). The HHcy patients also showed increased levels of
VCAM-1 (644 [567 to 767] vs. 519 [477 to 625] ng/ml,
 0.02) (Fig. 1B).
Consistently, plasma log Hcy levels positively correlated
ith both log sCD40L (R  0.68, R2  0.45, p  0.0001)
Fig. 2A) and log sVCAM-1 (R  0.30, R2  0.09, p 
.04) (results not shown). A weak correlation was also noted
Figure 2 Relationship Between SCD40L
and Homocysteine or sVCAM-1
Correlation between plasma levels of homocysteine (A) or sVCAM-1 (B) and
sCD40L in all included subjects. Dots represent individual measurements. For
correlation analysis, the Pearson correlation coefficient was calculated. The
insight scatterplots represent the correlation of untransformed variables. Log
homocysteine  logarithmic transformation of homocysteine; Log sCD40L 
logarithmic transformation of plasma sCD40L; Log sVCAM-1  logarithmic
transformation of sVCAM-1; other abbreviations as in Figure 1.
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Homocysteine and the CD40/CD40L Dyad June 5, 2007:2182–90etween log sCD40L and log sVCAM-1 (R  0.41, R2 
.16, p  0.005) (Fig. 2B).
To further evaluate the relationship between plasma
CD40L levels and laboratory and clinical variables, we
arried out a multiple linear regression analysis. This anal-
sis confirmed that log Hcy and log sVCAM-1 were the
ajor determinants of log sCD40L, independently from the
ther risk factors (Table 2).
cy regulates CD40 expression in HUVECs. Next, we
nalyzed the effect in vitro of Hcy on CD40 expression in
UVECs. The Hcy, at concentrations compatible with
evels reached in HHcy patients, determined a time- and
oncentration-dependent increase in CD40 protein expres-
ion. At these concentrations of Hcy, HUVECs viability
xceeded 95%. The CD40 expression was maximally stim-
lated by concentrations of Hcy between 100 and 500 M
Fig. 3A). As reported in Figure 3C, flow cytometric
nalysis showed that after 12-h exposure to 50 or 500 M
cy, the percentage of HUVECs expressing detectable
evels of CD40 increased from 8.9  0.4 to 12.4  1.8 and
9.3  8.1 (p  0.017 and p  0.045 vs. controls,
espectively). Stimulation was maintained up to 24-h incu-
ation. At this time, the percentage of CD40-expressing
ells increased from 14.7  0.06 in controls to 20.3  1.2
r 29.3  2.1 in cells treated with 50 or 500 M Hcy,
espectively (p  0.02 or p  0.00025 vs. controls). Similar
esults were obtained when we monitored CD40 protein
xpression by western blotting (Fig. 3D). Homocysteine
lso increased CD40 mRNA levels. Real-time polymerase
hain reaction measurements showed a peak increment of
183% (1.7  0.69 vs. 0.6  0.29 relative abundance, p 
.033) after 6-h incubation (Fig. 4). Thus, Hcy significantly
p-regulates CD40 expression in HUVECs.
cy potentiates CD40L-induced up-regulation of
CAM-1 in endothelial cells. To determine whether
Multiple Regression Analysis of Variables Assocodel (Regres ion Summary for Dependent Varip < 0.00005) and Final Model With St pwi e M
Table 2
Multiple Regression Analysis of Var
Model (Regression Summary for De
p < 0.00005) and Final Model With
Dependent Variable Explanatory Variable
Entire model
Log sCD40L
Log homocysteine
Log sVCAM-1
Diabetes
Venous thrombosis
Arterial Thrombosis
Smoking
Male
Dyslipidemia
Age
Arterial hypertension
Backward stepwise method
Log homocysteine
sCD40L  soluble CD40 ligand; sVCAM  soluble vascular cell adhesp-regulation of CD40 expression in endothelial cells was (ssociated with changes in CD40L activity, we exposed
UVECs to Hcy (100 M, 24 h) followed by sCD40L
500 ng/ml, 6 h) and evaluated VCAM-1 protein expression
y flow cytometry. Consistent with previous results with
uman aortic endothelial cells (HAECs) (20), Hcy in-
reased basal VCAM-1 expression levels from 5.1  2.5
FI to 11.3  2.6 MFI. The sCD40L greatly enhanced
CAM-1 expression (58.6  11.8 MFI). When cells were
retreated with Hcy, a significant increase in sCD40L-
nduced VCAM-1 expression was observed (from 58.6 
1.8 MFI to 78.4  11.0 MFI) (Fig. 5). We obtained
imilar results with HAECs (data not shown). These
ndings indicate that Hcy can potentiate CD40L-induced
esponses in endothelial cells.
D40 expression is also induced by oxidant stress and
ysteine. Oxidant species are generated during the auto-
xidation of Hcy to homocysteine (21). On the other hand,
rans-sulfuration of Hcy generates cysteine, which is also
onsidered a cardiovascular risk factor (22). Therefore, we
sked whether oxidative stress and/or cysteine may be
nvolved in the mechanism of CD40 up-regulation by Hcy.
or this purpose, we exposed HUVECs to hydrogen per-
xide (H2O2) or L-cysteine. We found that both H2O2and
-cysteine significantly up-regulated CD40 expression in
UVECs. In particular, H2O2 (300 M) increased the
ercentage of CD40-expressing cells from 27.6  7.7 to
3.6  7.5, p  0.031, whereas L-cysteine (500 M)
ncreased this percentage from 8.2  1.3 to 22.9  12.2,
 0.05) (Fig. 6). We also observed a modest, not
tatistically significant increase in CD40 expression when
UVECs were exposed to methionine (results not shown).
cy enhances CD40L expression in human platelets.
ecause sCD40L originates mainly from circulating plate-
ets, and Hcy levels are directly correlated with sCD40L
evels in patients carrying the MTHFR C677T mutation
With CD40L Levels; EntireR2  0.60, F  5.58;d
s Associated With CD40L Levels; Entire
ent Variable: R2  0.60, F  5.58;
pwise Method
gression Coefficient Standard Error p Value
0.62 0.116 0.000005
0.29 0.126 0.025959
0.23 0.125 0.075733
0.22 0.178 0.229542
0.16 0.266 0.559355
0.16 0.118 0.181270
0.15 0.132 0.268911
0.08 0.128 0.520118
0.01 0.281 0.969184
0.009 0.127 0.939829
0.68 0.107 0.001552
lecule.iatedabl :e ho
iable
pend
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ReFig. 2), we reasoned that Hcy may regulate CD40L
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June 5, 2007:2182–90 Homocysteine and the CD40/CD40L Dyadxpression in platelets. To verify this hypothesis, we exposed
ashed human platelets to an increasing concentration of
cy for varying times. Homocysteine up-regulated platelet
D40L expression, with a maximum when platelets were
ncubated with 500 M Hcy for 5 min (14.1  4.8 MFI to
1.4 6.2 MFI (p  0.025) (Fig. 7). Remarkably, throm-
in, which is considered a potent inducer of platelet
D40L, stimulated CD40L expression to a similar ex-
ent as Hcy (33.3  5.0 MFI, p  0.044) (Fig. 7),
ndicating that results with Hcy may be pathophysiologi-
ally relevant.
iscussion
n the present report, we present the first evidence of a
ignificant increase in sCD40L levels in individuals with
Figure 3 Impact of Hcy on CD40 Protein Expression in HUVECs
(A) The left panel shows untreated cells. The dashed histogram represents the ir
right panels show HUVECs exposed to respectively 50 M or 500 M Hcy for 24
cells. Each histogram is representative of at least 3 experiments and shows cell n
Increase in CD40 expression by Hcy in HUVECs is concentration dependent. Cells
12 h, and CD40 expression was evaluated by flow cytometry. Results are from a r
experiments with HUVECs exposed to the indicated concentrations of Hcy for 12 h
blot analysis. The HUVECs were exposed to the indicated concentrations of Hcy fo
SD of densitometric analyses from 3 separate experiments. Results were normaliz
HUVECs  human umbilical vein endothelial cells.Hcy expressing the MTHFR C677T genotype (Fig. 1A). (n addition, we show that Hcy, at concentrations that
ay be reached in patients with HHcy, up-regulates
D40 expression in HUVECs and CD40L in platelets
Figs. 3, 4, and 7). These results unravel a novel potential
athogenetic mechanism of HHcy-associated atherothrom-
osis, namely the up-regulation of CD40 signaling in
ascular cells.
The involvement of the CD40/CD40L dyad in vascular
nflammation and atherogenesis is now widely recognized
23). Increased sCD40L levels have been found in patients
ith a variety of cardiovascular disorders (11–16). In these
onditions, activated platelets may represent a major source
f sCD40L. It has been documented that sCD40L levels
re reduced by antiplatelet drugs (24), and positively corre-
ate with 11d-TXB2, an index of in vivo platelet activation
t antibody; the green histogram depicts the anti-CD40 antibody. The middle and
en histograms indicate untreated cells, open histograms depict Hcy-treated
rs (y axis) versus log fluorescence intensity (x axis) for 6.000 viable cells. (B)
xposed to increasing concentrations of Hcy (10, 25, 50, 100, 500 M) for
ntative experiment. (C) The graph summarizes results from 3 to 5 different
h. Data are expressed as mean  SD of percent of total events. (D) Western
. The upper panel shows a representative blot. The lower panel depicts mean 
-actin. Ctrl  control; FL1  fluorescent channel 1; Hcy  homocysteine;relevan
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umbe
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Homocysteine and the CD40/CD40L Dyad June 5, 2007:2182–90ave previously documented in vivo platelet activation in
Hcy (18) and report here that Hcy stimulated CD40L
xpression in isolated human platelets to a similar extent as
hrombin (Fig. 7). Thus, CD40L up-regulation by Hcy may
Figure 4 Time Course of CD40 mRNA Up-Regulation by Hcy
The HUVECs were exposed to either vehicle control (Ctrl) or Hcy (500 M) for
the indicated time. The CD40 messenger ribonucleic acid (mRNA) expression
was evaluated by real-time polymerase chain reaction. Relative CD40 abun-
dance was calculated using glyceraldehyde-3-phosphate dehydrogenase as
gene of reference and the equation 2Ct. Data points are mean  SD from
3 independent experiments. Abbreviations as in Figure 3.
Figure 5 Hcy Modulates the CD40/CD40L System
The HUVECs were exposed to vehicle control or to 100 M Hcy for 24 h and then
sion was measured by flow cytometry. (A) (Left panel) Dotted line  irrelevan
with Hcy. (Center panel) Filled histogram  vehicle-treated cells; open histogr
cells; open histogram  cells treated with Hcy  CD40L. (B) Bars represent m
Abbreviations as in Figures 1 and 3.e a consequence of platelet activation. This is consistent
ith early observations showing a very low level of CD40L
xpression in resting platelets (4). On the other hand,
ncreased CD40 expression in vascular cells of atheroscle-
otic lesions had been clearly documented (8). Engagement
f endothelial CD40 by platelet CD40L triggers a number
f proinflammatory responses, including release of inflam-
atory cytokines and expression of adhesion molecules,
uch as VCAM-1, which promotes recruitment of leuko-
ytes and progression of atherosclerosis (4). Thus, Hcy by
ncreasing circulating sCD40L levels (Fig. 1) and expression
f CD40 in endothelial cells (Figs. 3 and 4) and of CD40L
n platelets (Fig. 6) may promote CD40 signaling. Indeed,
e observed that exposure of HUVECs to Hcy significantly
otentiated VCAM-1 expression induced by sCD40L (Fig.
). This seems to be consistent with the observation that
ubjects with Hcy concentrations above 15 mol/l displayed
levated sVCAM-1 (Fig. 1). Although Hcy can directly
p-regulate VCAM-1 expression in endothelial cells (20)
Fig. 5), the contribution of a CD40-related circuit may be
elevant in vivo. Results in Figure 2, showing a significant
ositive correlation between sCD40L and sVCAM-1 levels,
upport this concept.
ted with 500 ng/ml CD40L for 6 h. Cells were harvested, and VCAM-1 expres-
ody; filled histogram  vehicle-treated cells; open histogram  cells treated
cells exposed to CD40L. (Right panel) Filled histogram  vehicle-treated
SEM of mean fluorescence intensity (MFI) from 3 independent experiments.incuba
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June 5, 2007:2182–90 Homocysteine and the CD40/CD40L DyadHomocysteine may alter endothelial cell functions by
ultiple and still incompletely elucidated mechanisms. We
ave recently reported that severe HHcy is associated with
ncreased peroxidation of arachidonic acid in vivo (18).
thers have shown that exposure to Hcy triggers generation
f reactive oxygen species (26,27) and that Hcy impairs the
ntioxidant potential of endothelial cells (28). Thus, some
cy bioactions may be related to the induction of oxidative
amage. Our present results, showing that hydrogen perox-
de significantly increases CD40 expression in HUVECs
Figure 6 Effect of H2O2 and L-cysteine on
CD40 Glycoprotein Expression in HUVECs
(A) The upper left panel shows untreated cells (the open histogram represents
the irrelevant antibody, whereas the blue histogram depicts the anti-CD40 anti-
body). The upper right panel shows a comparison between untreated cells
(blue histogram) and cells treated with H2O2 (300 M) for 30 min (open histo-
gram). Cells were washed and cultured in normal medium for 24 h before flow
cytometric analysis (upper panels). The graph in the lower panel shows mean
 SD from 3 different experiments. (B) The upper left panel shows untreated
cells (the open histogram represents the irrelevant antibody, whereas the blue
histogram depicts the anti-CD40 antibody). The upper right panel shows a
comparison between untreated cells (blue histogram) and cells treated with
L-cysteine (500 M) for 12 h. The lower panel shows mean  SD from 3 sep-
arate experiments. Ctrl  control; other abbreviations as in Figure 3.Fig. 5), suggest that oxidative events may be involved incy-induced CD40 up-regulation. This is an intriguing
spect. It is, in fact, known that CD40 activation by its
igand stimulates production of reactive oxygen species (29).
hus, up-regulation of CD40 by oxidant damage may
epresent a mechanism of amplification of CD40L-induced
roinflammatory responses. However, the molecular events
nvolved in CD40 stimulation by Hcy in HUVECs remain
o be fully elucidated. Because CD40 expression in vascular
ells is under the control of the transcription factor nuclear
actor (NF)-
 (30) and Hcy stimulates NF-
 activity in
UVECs via generation of superoxide anion (27), it may be
easoned that CD40 up-regulation by Hcy may proceed
hrough NF-B activation. On the other hand, products
enerated during Hcy metabolism also may play a role in the
athogenesis of atherothrombosis. In particular, cysteine is
onsidered a cardiovascular risk factor (22), whereas a recent
eport emphasizes the role of methionine in atherogenesis
31). In our experimental conditions, L-cysteine was as
otent as Hcy at inducing CD40 expression (Fig. 5),
hereas results with methionine were less consistent, al-
hough some increase in CD40 expression could be ob-
erved. Thus, it may be hypothesized that at least part of the
cy effects on CD40 expression may be related to its
etabolic conversion to cysteine. On the other hand,
ysteine is known to potentiate the capability of Hcy to
xidate low-density lipoprotein (32), suggesting that both
cy and cysteine may converge on pro-oxidant pathways to
p-regulate CD40.
Figure 7 Homocysteine Stimulates CD40L
Expression in Washed Human Platelets
Platelets (1  108 /ml) were exposed to Homocysteine (Hcy) (500 M) or
thrombin (Thr) (0.2 U/ml) for 5 min at 37°C and analyzed by flow cytometry.
(A) Filled histograms represent untreated cells, whereas open histograms rep-
resent cells exposed to Hcy or Thr. Staining with irrelevant nonbinding antibody
is indicated by dotted histograms. (B) Bars represent mean  SD of mean
fluorescence intensity (MFI) from 3 independent experiments. Ctrl  control;
other abbreviations as in Figure 3.
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Homocysteine and the CD40/CD40L Dyad June 5, 2007:2182–90In conclusion, our present results showing a previously
nappreciated relationship between Hcy and the CD40/
D40L dyad in vivo and in vitro provide novel evidence of
he role that HHcy may play in the pathogenesis of
therothrombosis.
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